Marinomed Biotech Investor Relations Material
Latest events
Q1 2024
Marinomed Biotech
H2 2024
16 Apr, 2025
H1 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Marinomed Biotech AG
Access all reports
Marinomed Biotech AG is an Austrian biotechnology company specializing in antiviral and immunology products. The company develops therapies based on proprietary technology platforms for treating respiratory and ocular diseases. It focuses on both prescription and over-the-counter formulations with applications in global healthcare markets. The company is headquartered in Korneuburg, Austria, and its shares are listed on the VSE.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
MARI
Country
🇦🇹 Austria